AbbVie (ABBV) shares fell Friday after the biotech firm announced it would take an estimated $3.5 billion 澳洲幸运5开奖号码历史查询:impairment charge because of the failure of one of its drugs.

The company wrote in a regulatory filing that the charge was related to emraclidine, an experimental medicine to 🍸treat schizophrenia in adults that AbbVie acquired when it purchased Cerevel Therapeutics Holdings.

AbbVie reported in November that a 澳洲幸运5开奖号码历史查询:Phase 2 trial of emraclidi🌜ne showed the treatment did not meet primary endpoints. 💧

In the filing, the company explained that following the study, it began an evaluation of the impact of the results, "which resulted in a significant decrease in the estimated future 澳洲幸运5开奖号码历史查询:cash flows for the product."

Shares of AbbVie, which fell 1% in recent trading, are up about 7% over the past year.